


## VPC-3033

Cat. No.:	HY-118409
CAS No.:	110763-24-1
Molecular Formula:	C <sub>21</sub> H <sub>14</sub> O <sub>2</sub>
Molecular Weight:	298.33
Target:	Androgen Receptor
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

### Description

VPC-3033 is an androgen receptor antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC<sub>50</sub>: 0.625-2.5 μM), can effectively inhibit androgen receptor transcriptional activity (IC<sub>50</sub>=0.3 μM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002)<sup>[1]</sup>.

## REFERENCES

[1]. Li H, et al. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer[J]. Molecular cancer therapeutics, 2013, 12(11): 2425-2435.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA